jaw deformity
Conditions
Interventions
A group of patients receive an intravenous bolus of 1mg granisetron (KYTRIL) at the end of orthognathic surgery. To evaluate the incidence rate and intensity of PONV and number of rescue at four time
Sponsors
Kyoto jaw deformity center, Rakuwakai Otowa Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Jaw deformity patients that are eligible for orthognathic surgery at Kyoto jaw deformity center. They are American Society of Anesthesiology (ASA) 1 or 2 status. A research associate described the research to each subject and obtained written consent or assent with parental permission.
Exclusion criteria
Exclusion criteria: Patients without consent of the research. Patients with allergy with granisetron.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the incidence rate and intensity of PONV and number of rescue antiemetics (metoclopramide) at four time points for the 24-h study period after orthognathic surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Nausea intensity is measured using a numeric rating scale. To evaluate safely by incidence of adverse effects as drug-induced liver injury and allergy or anaphylaxis at four time points (0-2h, 2-6h, 6-12h, and 12-24h interval). Rescue drug, metoclopramide is given 10mg intravenously. | — |
Countries
Japan
Contacts
Public ContactHiroki Mori
Rakuwakai Otowa Hospital Kyoto jaw deformity center
Outcome results
None listed